Nicotinamide, a vitamin B3 derivative, could significantly reduce skin cancer risk. The corresponding study was published in JAMA Dermatology.

“There are no guidelines for when to start treatment with nicotinamide for skin cancer prevention in the general population,” said the study’s corresponding author, Lee Wheless, MD, PhD, assistant professor of Dermatology and Medicine at Vanderbilt University Medical Center in a press release.

“These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier,” he added.